Hot Flashes Market Insights, Epidemiology and Market Forecast 2016-2018 & 2027 - ResearchAndMarkets.com

September 18, 2018

DUBLIN--(BUSINESS WIRE)--Sep 18, 2018--The “Hot Flashes - Market Insights, Epidemiology and Market Forecast-2027” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Hot Flashes - Market Insights, Epidemiology and Market Forecast-2027′ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hot Flashes in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Hot Flashes from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered:

The United States EU5 (Germany, France, Italy, Spain and the United Kingdom) Japan

Study Period: 2016-2027

Key Topics Covered:

1. Key Insights

2. Hot Flashes: Market Overview at a Glance

2.1. Total Market Share (%) Distribution of Hot Flashes in 2016

2.2. Total Market Share (%) Distribution of Hot Flashes in 2027

3. Hot Flashes associated with menopause: Disease Background and Overview

3.1. Introduction

3.2. Vasomotor Symptoms

3.3. Signs and Symptoms of VMS

3.4. Pathophysiology of VMS

3.5. Risk factors for VMS

3.6. Effects of VMS

3.7. Premature (early) Menopause

3.8. Menopause Associated with Breast Cancer Treatment

4. Epidemiology and Patient Population

5. Total Prevalent Patient Population of Hot Flashes associated with Post-menopause in 7MM Countries

6. Country Wise-Epidemiology of Hot Flashes Associated with Post-menopause

6.1. Assumptions and Rationale

6.2. Total Prevalent Population of Hot Flashes Associated with Post-menopause

6.3. Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause

7. Treatment Algorithm, Current Treatment, and Medical Practices

7.1. Hormonal Therapies

7.1.1. Estrogen Replacement Therapies

7.1.2. Progestational Agents

7.2. Non-hormonal pharmacological treatments for vasomotor symptoms

7.2.1. Clonidine

7.2.2. Serotonin Reuptake Inhibitors

7.2.3. Gabapentin

7.2.4. Behavioral Modifications

7.3. Complementary alternative medicines (CAM):

8. Unmet Needs

9. Marketed drugs by class

9.1. Hormonal Therapies

9.1.1. Estrogen Only Therapies

9.1.2. Combination Therapies

9.2. Non-Hormonal Therapies

9.2.1. Approved Drug

9.2.2. Off-Label Antidepressants

10. Emerging Therapies

10.1. Key Cross Competition

10.2. TX-001HR: TherapeuticsMD

10.3. BHR-401 (Utrogestan): Besins Healthcare

10.4. Prasterone + Acolbifene: Endoceutics

10.5. MT-8554: Mitsubishi Tanabe Pharma

10.6. ESN364: Ogeda

10.7. NT-814: Nerre Therapeutics

10.8. Salubrin: Pherin Pharmaceuticals

10.9. Donesta: Mithra Pharmaceuticals (Donesta Biosciences)

10.10. FP-101: Fervent Pharmaceuticals

10.11. MLE4901 (AZD4901): Millendo Therapeutics

11. Hot Flashes: 7 Major Market Analysis

11.1. Key Findings

11.2. Market Size of Hot Flashes associated with Post Menopause in 7MM

11.3. Market Size by Therapies in 7MM

12. The United States Market Outlook

12.1. United States Market Size

12.2. Total Market size of Hot Flashes in the United States

12.3. Market Size by Therapies in the United States

13. EU-5 Countries: Market Outlook

14. Market Drivers

15. Market Barriers

16. Appendix

Companies Mentioned

TherapeuticsMD Besins Healthcare Endoceutics Mitsubishi Tanabe Pharma Ogeda Nerre Therapeutics Pherin Pharmaceuticals Mithra Pharmaceuticals, Fervent Pharmaceuticals Millendo Therapeutics For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/44rv8f/hot_flashes?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180918005895/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Sexual and Reproductive Health Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/18/2018 12:42 PM/DISC: 09/18/2018 12:42 PM


Update hourly